Department of Comparative Medicine, Stanford University, Stanford, California.
Department of Mathematics, Naresuan University, Phitsanulok, Thailand.
J Am Assoc Lab Anim Sci. 2022 Sep 1;61(5):448-456. doi: 10.30802/AALAS-JAALAS-22-000058. Epub 2022 Sep 6.
Buprenorphine is perhaps the most prescribed analgesic for management of postoperative pain in mice. Although various buprenorphine formulations are effective in commonly used immunocompetent mouse strains, a knowledge gap exists regarding its efficacy in immunodeficient mice. Here we used a plantar incision to evaluate the efficacy of 3 buprenorphine formulations for attenuating postoperative mechanical and thermal hypersensitivity in the immunodeficient NSG mouse strain. We also characterized the pharmacokinetics of these formulations over a 72-h period. We hypothesized that all 3 buprenorphine formulations evaluated-the standard preparation and 2 extended-release products (Bup-HCl, Bup-ER, and Bup-XR, respectively)-would attenuate postoperative mechanical and thermal hypersensitivity resulting from a plantar incision in NSG mice. Male and female NSG mice ( = 48) were allocated to 4 treatment groups: saline (0.9% NaCl, 5 mL/kg SC once); Bup-HCl (0.1 mg/kg SC, BID for 2 d); Bup-ER (1.0 mg/kg SC once); and Bup-XR (3.25 mg/kg SC once). Mechani- cal and thermal hypersensitivity assessments were conducted 24 h before surgery and at 4, 8, 24, 48, and 72 h afterward. All groups of mice showed mechanical and thermal hypersensitivity within the first 24 h after surgery. Behavioral pain indicators (guarding, toe-touching [intermittent partial weight bearing], licking the incision, vocalizations) were observed in some mice from each group at every postoperative time point. Plasma buprenorphine was measured in a separate group of mice and concentrations surpassed the suggested therapeutic level (1.0 ng/mL) for less than 4 h for Bup-HCl, for at least 24 h for Bup-ER, and for 72 h for Bup-XR. Our results indicate that at the dosages studied, these buprenorphine formulations do not adequately attenuate postoperative mechanical and thermal hypersensitivity in the plantar incisional model in NSG mice. These findings support the need for strain-specific analgesic protocols for mice used in research.
丁丙诺啡或许是术后疼痛管理中最常被开具的一种阿片类镇痛药物。尽管各种丁丙诺啡制剂在常用的免疫功能正常的小鼠品系中均有效,但在免疫缺陷小鼠中,其疗效尚存在知识空白。在这里,我们使用足底切口评估了 3 种丁丙诺啡制剂在 Attenuating 免疫缺陷 NSG 小鼠足底切口术后机械和热痛觉过敏中的疗效。我们还在 72 小时内对这些制剂的药代动力学进行了特征描述。我们假设评估的 3 种丁丙诺啡制剂(标准制剂和 2 种延长释放产品,分别为 Bup-HCl、Bup-ER 和 Bup-XR)均能减轻 NSG 小鼠足底切口术后机械和热痛觉过敏。雄性和雌性 NSG 小鼠(=48)被分配到 4 个治疗组:生理盐水(0.9% NaCl,5 mL/kg,SC 单次);Bup-HCl(0.1 mg/kg,SC,BID 2 天);Bup-ER(1.0 mg/kg,SC,单次);Bup-XR(3.25 mg/kg,SC,单次)。在手术前 24 小时和术后 4、8、24、48 和 72 小时进行机械和热痛觉过敏评估。所有组别的小鼠在手术后的前 24 小时内均表现出机械和热痛觉过敏。在每个术后时间点,从每组中的一些小鼠观察到行为疼痛指标(守卫、脚趾触摸[间歇性部分负重]、舔切口、发声)。在另一组小鼠中测量了血浆丁丙诺啡,Bup-HCl 的浓度在不到 4 小时内超过建议的治疗水平(1.0ng/mL),Bup-ER 至少 24 小时,Bup-XR 则为 72 小时。我们的结果表明,在所研究的剂量下,这些丁丙诺啡制剂并不能充分减轻 NSG 小鼠足底切口术后的机械和热痛觉过敏。这些发现支持为用于研究的小鼠制定特定于品系的镇痛方案。